Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.

Jocelyn ChanJohn J KimBrett K BarrettAbdullah HamadehJordan J FeldWilliam W L Wong

Published in: Journal of viral hepatitis (2020)

This analysis informs payers that SOF/VEL should continue to be reimbursed in decompensated hepatitis C patients. It also supports the recommendations by the American Association for the Study of Liver Diseases to continue screening for HCC in decompensated cirrhotic patients who have achieved sustained virologic response.

Keyphrases

ejection fraction
end stage renal disease
heart failure
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
hepatitis b virus
liver failure
patient reported
patient reported outcomes